Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL

ABSTRACT Objective To analyze the contribution of multiparametric MRI and PCA3 assay, pre- decision of initial biopsy in PSA level between 3-10 ng/mL patients with normal digital rectal examination(DRE). Materials and Methods PSA level 3-10 ng/mL ,patients, with normal DRE results and no previou...

Full description

Bibliographic Details
Main Authors:	Sezgin Okcelik, Hasan Soydan, Ferhat Ates, Ufuk Berber, Hasan Saygin, Güner Sönmez, Kenan Karademir
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2016-06-01
Series:	International Brazilian Journal of Urology
Subjects:	prostate cancer antigen 3 human [Supplementary Concept] Prostate Magnetic Resonance Imaging
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000300449&lng=en&tlng=en

Similar Items

Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values
by: Hasan Yilmaz, et al.
Published: (2015-06-01)

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml
by: Emerson P. Gregorio, et al.
Published: (2007-04-01)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml-1
by: Cheng Wang, et al.
Published: (2021-01-01)

Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis
by: S. Fontenete, et al.
Published: (2011-12-01)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
by: I. Vukovic, et al.

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
by: Tsung-Hsin Chang, et al.
Published: (2020-10-01)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
by: W. F. S. Busato, et al.
Published: (2015-04-01)

Decision Tree Analysis for Prostate Cancer Prediction in Patients with Serum PSA 10 ng/ml or Less
by: Pantic Damjan N, et al.
Published: (2020-03-01)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml -1 and 10.1-20.0 ng ml -1 : a multicenter study
by: Yu-Rong Lin, et al.
Published: (2015-06-01)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1
by: Lincoln GL Tan, et al.
Published: (2017-01-01)

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report
by: Michael H. Johnson, et al.
Published: (2015-09-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1)
by: Jun Liu, et al.
Published: (2020-01-01)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
by: Hugo A. Socrates Castro, et al.

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
by: Peter F. A. Mulders, et al.
Published: (2013-05-01)

THE INCIDENCE AND CORRELATION OF CHRONIC PROSTATITIS WITH PSA IN BPH PATIENT
by: Daniel Mahendra Krisna, et al.
Published: (2018-07-01)

Incidence of histological prostatitis and its correlation with PSA density
by: Affonso Celso Piovesan, et al.
Published: (2009-11-01)

Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade
by: Aradhana M. Venkatesan, et al.
Published: (2021-01-01)

Histomorphologic Correlation of PSA Levels in Prostatic Pathology
by: Deepak Panasseril Jayapradeep, et al.
Published: (2017-10-01)

PSA screening for prostate cancer
by: Marcus V. Sadi

Predictors of Clinically Significant Prostate Cancer: A Comparative Study of PSA, PSA Density, and MRI Parameters
by: Mehmet Coşkun, et al.
Published: (2021-02-01)

Performance of PSA and of PSA density in the diagnosis of prostate carcinoma
by: Antonio Carlos Pereira Martins, et al.
Published: (2002-01-01)

Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies
by: Ömer Yilmaz, et al.

Evaluation of mucin histochemistry in benign and malignant prostatic lesion and their correlationPSA level
by: S Bastola, et al.
Published: (2014-11-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
by: Hayley Pye, et al.
Published: (2021-04-01)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Prostate – Specific Antigen (Psa) as a Screening Tool for Benign Prostate Hyperplasia (Bph) and Prostate Cancer (Pca) in Sulaimani Province
by: Sirwan M. Muhammad, et al.
Published: (2013-09-01)

PSA kinetics before 40 years of age
by: Cristiano Linck Pazeto, et al.

Histopathological findings in extended prostate biopsy with PSA ≤ 4 ng/mL
by: Katia R. Leite, et al.
Published: (2008-06-01)

AGE, TOTAL PSA, PSA DENSITY AND GLEASON SCORE, TAUS AS PREDICTIVE FACTORS IN PATIENTS WITH PROSTATE CANCER
by: Daruqutni Albar, et al.
Published: (2016-03-01)

PCA3 and PCA3-Based Nomograms Improve Diagnostic Accuracy in Patients Undergoing First Prostate Biopsy
by: Virginie Vlaeminck-Guillem, et al.
Published: (2013-08-01)

Developing Strategy to Predict the Results of Prostate Multiparametric Magnetic Resonance Imaging and Reduce Unnecessary Multiparametric Magnetic Resonance Imaging Scan
by: Junxiao Liu, et al.
Published: (2021-09-01)

Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology
by: Andrea B. Galosi, et al.
Published: (2021-03-01)

Comparison of Pathology and Prevalence of Prostate Cancer in Patients with PSA between 4-10 ng/ml
by: A Tabibi, et al.
Published: (2008-01-01)

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
by: Jaegeun Lee, et al.
Published: (2021-04-01)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
by: Alexandros Fiamegos, et al.

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
by: Jin-Woo Jung, et al.
Published: (2019-01-01)

Association of Connexin 32 with Prostate Volume and PSA Level in Prostatic Adenocarcinoma and Adenomyomatous Hyperplasia
by: Havva Erdem, et al.
Published: (2020-06-01)